

Table 3 Five-year EFS and OS estimate with 95% CI by protocol

		5-year EFS (95% CI)	5-year OS (95% CI)
Cohort	RMS2005	49% (38.80%- 59.25%)	51% (40.90%-60.87%)
Cohort	ARST0531	44% (29.96%- 58.14%)	53.6% (39.61%-67.69%)
FOXO1 fusion negative (cohorts combined)		63% (44.61%- 81.03%)	69% (51.71%-86.26%)
FOXO1 fusion positive (cohorts combined)		47.6% (37.21%- 58.06%)	52.7% (42.62%-62.93%)
FOXO1 fusion status for RMS2005	Negative	73 % (53.00%- 92.76%)	76% (57.22%-94.89%)
	Positive	49.3 % (35.80%- 62.79%)	51.6% (38.57%-64.71%)
FOXO1 fusion status for ARST0531	Negative	43.8% (6.62%-80.88%)	56.2% (19.79%-92.71%)
	Positive	45% (28.76%- 61.53%)	53.7% (37.74%-69.79%)
Primary site (cohorts combined)	Extremities	38% (23.77%- 52.22%)	50% (35.87%-64.17%)
	Parameningea l	46.5% (30.79%- 62.22%)	47.4% (31.51%-63.27%)
	All other sites	55.5% (42.51%- 68.58%)	57% (44.19%-69.69%)